Symbols / CDNA Stock $27.85 +2.65% CareDx, Inc.

Healthcare • Diagnostics & Research • United States • NGM
CDNA (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Diagnostics & Research
CEO Mr. John Walter Hanna Jr.
Exch · Country NGM · United States
Market Cap 1.44B
Enterprise Value 1.28B
Income -8.19M
Sales 412.82M
FCF (ttm) 70.14M
Book/sh 6.12
Cash/sh 3.62
Employees 761
Insider 10d —
IPO Jul 17, 2014
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E 24.56
PEG —
P/S 3.49
P/B 4.55
P/C —
EV/EBITDA 550.97
EV/Sales 3.09
Quick Ratio 2.93
Current Ratio 3.40
Debt/Eq 7.81
LT Debt/Eq —
EPS (ttm) -0.16
EPS next Y 1.13
EPS Growth —
Revenue Growth 39.00%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-04-28
Earnings (prior) 2026-04-28
ROA -1.80%
ROE -2.37%
ROIC —
Gross Margin 68.88%
Oper. Margin 1.53%
Profit Margin -1.98%
Shs Outstand 51.66M
Shs Float 49.27M
Insider Own 3.47%
Instit Own 101.82%
Short Float 16.64%
Short Ratio 11.22
Short Interest 8.43M
52W High 28.42
vs 52W High -2.01%
52W Low 10.96
vs 52W Low 154.11%
Beta 2.48
Impl. Vol. 9.38%
Rel Volume 1.65
Avg Volume 797.21K
Volume 1.32M
Target (mean) $25.80
Tgt Median $26.00
Tgt Low $21.00
Tgt High $28.00
# Analysts 5
Recom Buy
Prev Close $27.13
Price $27.85
Change 2.65%
About

CareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally. The company provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression profiling solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. It also offers HeartCare, which provides information about distinct biological processes, such as immune quiescence, active injury, acute cellular rejection, and antibody mediated rejection; HistoMap Kidney, a solution that identifies allograft rejection and type of rejection in kidney transplant biopsy tissue; and AlloHeme, a monitoring test that predicts relapse in patients with acute myeloid leukemia and myelodysplastic syndromes. In addition, the company provides QTYPE that enables precision in human leukocyte antigen (HLA) typing; Olerup SSP, which is used to type HLA alleles based on sequence specific primer technology; and Ottr, a transplant patient management software. Further, it offers AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a solution that monitors the pharmacokinetics of engraftment and persistence of cells for patients who have received allogeneic cell therapy; and XynQAPI, MedActionPlan, CareDx pharmacy, AlloHome, and HLA Data Systems software solutions. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in Brisbane, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$25.80
Mean price target
2. Current target
$27.85
Latest analyst target
3. DCF / Fair value
$24.44
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$27.85
Low
$21.00
High
$28.00
Mean
$25.80

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-29 main BTIG Buy → Buy $28
2026-02-26 main BTIG Buy → Buy $26
2026-02-25 main Wells Fargo Equal-Weight → Equal-Weight $21
2025-12-15 main Wells Fargo Equal-Weight → Equal-Weight $18
2025-11-06 main BTIG Buy → Buy $25
2025-09-23 reit BTIG Buy → Buy $22
2025-09-12 reit BTIG Buy → Buy $22
2025-08-26 init William Blair — → Market Perform —
2025-08-08 main Wells Fargo Equal-Weight → Equal-Weight $14
2025-07-18 main Craig-Hallum Buy → Buy $26
2025-05-05 reit Stephens & Co. Overweight → Overweight $40
2025-05-05 reit HC Wainwright & Co. Neutral → Neutral $25
2025-04-17 main Goldman Sachs Buy → Buy $26
2025-03-03 main HC Wainwright & Co. Neutral → Neutral $25
2025-02-27 reit Stephens & Co. Overweight → Overweight $40
2025-01-15 up Wells Fargo Underweight → Equal-Weight $24
2025-01-14 reit HC Wainwright & Co. Neutral → Neutral $26
2024-11-05 main BTIG Buy → Buy $35
2024-10-22 reit HC Wainwright & Co. — → Neutral —
2024-10-16 main Goldman Sachs Buy → Buy $35
News
RSS: Latest CDNA news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-06-15 HANNA JOHN WALTER JR Chief Executive Officer — 17,683 $24.03 $424,877
2026-06-15 VALANTINE HANNAH A. Director — 12,103 $23.11 $279,728
2026-06-12 GUNASEKARAN SURESH Director — 9,795 $0.00 $0
2026-06-12 COURNOYER CHRISTINE M Director — 9,795 $0.00 $0
2026-06-12 COHEN FREDERICK E. M.D. PH.D. Director — 9,795 $0.00 $0
2026-06-12 RIGGSBEE RICHARD BRYAN Director — 9,795 $0.00 $0
2026-06-12 GOLDBERG MICHAEL D Director — 9,795 $0.00 $0
2026-06-12 BICKERSTAFF GEORGE W III Director — 9,795 $0.00 $0
2026-06-12 VALANTINE HANNAH A. Director — 9,795 $0.00 $0
2026-06-11 HANNA JOHN WALTER JR Chief Executive Officer — 21,998 $24.02 $528,443
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
379.81
+13.79%
333.79
+19.07%
280.32
-12.89%
321.79
Operating Revenue
379.81
+13.79%
333.79
+19.07%
280.32
-12.89%
321.79
Cost Of Revenue
123.24
+12.35%
109.70
+7.48%
102.07
-9.04%
112.21
Reconciled Cost Of Revenue
123.24
+12.35%
109.70
+7.48%
102.07
-9.04%
112.21
Gross Profit
256.57
+14.49%
224.09
+25.71%
178.26
-14.95%
209.58
Operating Expense
281.64
+0.72%
279.62
-2.00%
285.32
-0.52%
286.81
Research And Development
71.43
-1.49%
72.51
-12.02%
82.42
-8.81%
90.39
Selling General And Administration
210.21
+1.49%
207.11
+2.08%
202.90
+3.30%
196.42
Selling And Marketing Expense
102.64
+25.21%
81.97
-2.48%
84.06
-12.46%
96.03
General And Administrative Expense
107.56
-14.04%
125.14
+5.30%
118.84
+18.37%
100.40
Other Gand A
107.56
-14.04%
125.14
+5.30%
118.84
+18.37%
100.40
Total Expenses
404.88
+4.00%
389.32
+0.50%
387.39
-2.92%
399.02
Operating Income
-25.07
+54.86%
-55.53
+48.13%
-107.06
-38.63%
-77.23
Total Operating Income As Reported
-30.78
-175.51%
40.77
+120.05%
-203.36
-163.32%
-77.23
EBITDA
-4.66
+86.99%
-35.78
+58.99%
-87.24
-42.49%
-61.22
Normalized EBITDA
1.05
+100.80%
-132.08
-1557.65%
9.06
+114.77%
-61.33
Reconciled Depreciation
20.42
+3.34%
19.76
-0.34%
19.82
+23.85%
16.01
EBIT
-25.07
+54.86%
-55.53
+48.13%
-107.06
-38.63%
-77.23
Total Unusual Items
-5.71
-105.93%
96.30
+200.00%
-96.30
-90100.00%
0.11
Total Unusual Items Excluding Goodwill
-5.71
-105.93%
96.30
+200.00%
-96.30
-90100.00%
0.11
Special Income Charges
-5.71
-105.93%
96.30
+200.00%
-96.30
0.00
Other Special Charges
5.71
+105.93%
-96.30
-200.00%
96.30
—
Restructuring And Mergern Acquisition
—
1.78
-23.15%
2.32
0.00
Net Income
-21.35
-140.64%
52.55
+127.62%
-190.28
-148.37%
-76.61
Pretax Income
-21.08
-139.89%
52.86
+127.80%
-190.14
-149.42%
-76.23
Net Non Operating Interest Income Expense
9.17
-22.02%
11.77
-0.86%
11.87
+215.44%
3.76
Net Interest Income
9.17
-22.02%
11.77
-0.86%
11.87
+215.44%
3.76
Interest Income Non Operating
9.17
-22.02%
11.77
-0.86%
11.87
+215.44%
3.76
Interest Income
9.17
-22.02%
11.77
-0.86%
11.87
+215.44%
3.76
Other Income Expense
-5.19
-105.37%
96.63
+201.77%
-94.95
-3333.89%
-2.77
Other Non Operating Income Expenses
0.52
+59.27%
0.33
-75.68%
1.35
+147.11%
-2.87
Gain On Sale Of Security
—
—
0.01
-90.65%
0.11
Tax Provision
0.27
-12.58%
0.31
+119.86%
0.14
-62.80%
0.38
Tax Rate For Calcs
0.00
+3400.00%
0.00
-97.14%
0.00
+0.00%
0.00
Tax Effect Of Unusual Items
-1.20
-307.53%
0.58
+102.86%
-20.22
-90100.00%
0.02
Net Income Including Noncontrolling Interests
-21.35
-140.64%
52.55
+127.62%
-190.28
-148.37%
-76.61
Net Income From Continuing Operation Net Minority Interest
-21.35
-140.64%
52.55
+127.62%
-190.28
-148.37%
-76.61
Net Income From Continuing And Discontinued Operation
-21.35
-140.64%
52.55
+127.62%
-190.28
-148.37%
-76.61
Net Income Continuous Operations
-21.35
-140.64%
52.55
+127.62%
-190.28
-148.37%
-76.61
Normalized Income
-16.84
+60.99%
-43.17
+62.20%
-114.21
-48.91%
-76.70
Net Income Common Stockholders
-21.35
-140.64%
52.55
+127.62%
-190.28
-148.37%
-76.61
Diluted EPS
-0.40
-143.01%
0.93
+126.27%
-3.54
-145.83%
-1.44
Basic EPS
-0.40
-140.00%
1.00
+128.25%
-3.54
-145.83%
-1.44
Basic Average Shares
53.29
+0.97%
52.77
-1.84%
53.76
+0.83%
53.32
Diluted Average Shares
53.29
-5.89%
56.62
+5.31%
53.76
+0.83%
53.32
Diluted NI Availto Com Stockholders
-21.35
-140.64%
52.55
+127.62%
-190.28
-148.37%
-76.61
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
413.23
-15.85%
491.05
+5.19%
466.83
-14.03%
542.99
Current Assets
257.13
-26.92%
351.83
+12.15%
313.71
-19.11%
387.85
Cash Cash Equivalents And Short Term Investments
177.21
-32.01%
260.65
+10.72%
235.42
-19.68%
293.09
Cash And Cash Equivalents
65.43
-42.95%
114.69
+39.53%
82.20
-8.59%
89.92
Other Short Term Investments
111.78
-23.42%
145.96
-4.74%
153.22
-24.58%
203.17
Receivables
42.63
-34.02%
64.61
+26.53%
51.06
-23.00%
66.31
Accounts Receivable
42.63
-34.02%
64.61
+26.53%
51.06
-23.00%
66.31
Inventory
26.70
+36.93%
19.50
+0.16%
19.47
+1.24%
19.23
Raw Materials
13.16
+20.84%
10.89
+2.53%
10.62
-11.22%
11.96
Work In Process
3.74
-1.40%
3.79
-26.93%
5.19
+20.55%
4.31
Finished Goods
9.80
+103.44%
4.82
+31.74%
3.66
+23.50%
2.96
Prepaid Assets
—
—
—
—
Other Current Assets
10.59
+49.78%
7.07
-8.91%
7.76
-15.77%
9.22
Total Non Current Assets
156.10
+12.12%
139.22
-9.07%
153.11
-1.31%
155.14
Net PPE
55.73
-3.73%
57.89
-11.12%
65.14
-7.24%
70.22
Gross PPE
94.58
-0.27%
94.83
-2.63%
97.40
+2.91%
94.64
Accumulated Depreciation
-38.85
-5.17%
-36.94
-14.50%
-32.26
-32.10%
-24.42
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
45.37
+12.16%
40.45
-1.20%
40.94
+17.23%
34.92
Construction In Progress
8.28
-30.64%
11.94
+43.72%
8.31
+8.73%
7.64
Other Properties
22.76
-6.49%
24.34
-18.57%
29.89
-13.83%
34.69
Leases
18.17
+0.36%
18.11
-0.84%
18.26
+5.00%
17.39
Goodwill And Other Intangible Assets
72.30
-7.93%
78.52
-8.74%
86.04
+6.78%
80.57
Goodwill
40.34
+0.00%
40.34
+0.00%
40.34
+7.50%
37.52
Other Intangible Assets
31.96
-16.30%
38.18
-16.45%
45.70
+6.16%
43.05
Investments And Advances
24.16
0.00
—
—
Other Investments
24.16
0.00
—
—
Other Non Current Assets
3.90
+39.13%
2.81
+44.71%
1.94
-55.43%
4.35
Total Liabilities Net Minority Interest
110.13
-2.21%
112.62
-45.20%
205.50
+83.35%
112.08
Current Liabilities
89.85
+0.53%
89.37
+14.47%
78.07
+2.76%
75.97
Payables And Accrued Expenses
37.07
-7.52%
40.09
-2.55%
41.14
-5.94%
43.74
Payables
9.99
+29.95%
7.69
-40.29%
12.87
+29.47%
9.94
Accounts Payable
9.99
+29.95%
7.69
-40.29%
12.87
+29.47%
9.94
Current Accrued Expenses
27.09
-16.40%
32.40
+14.63%
28.27
-16.36%
33.80
Pensionand Other Post Retirement Benefit Plans Current
38.11
-0.59%
38.33
+94.55%
19.70
+16.57%
16.90
Current Debt And Capital Lease Obligation
6.51
+6.75%
6.10
+2.69%
5.94
+6.30%
5.59
Current Capital Lease Obligation
6.51
+6.75%
6.10
+2.69%
5.94
+6.30%
5.59
Current Deferred Liabilities
4.65
-4.02%
4.85
-14.47%
5.67
-23.45%
7.40
Current Deferred Revenue
4.65
-4.02%
4.85
+2.11%
4.75
-11.12%
5.34
Other Current Liabilities
—
2.54
-54.80%
5.62
+140.07%
2.34
Total Non Current Liabilities Net Minority Interest
20.28
-12.77%
23.25
-81.76%
127.43
+252.93%
36.10
Long Term Debt And Capital Lease Obligation
19.68
-11.61%
22.26
-21.27%
28.28
-15.35%
33.41
Long Term Capital Lease Obligation
19.68
-11.61%
22.26
-21.27%
28.28
-15.35%
33.41
Non Current Deferred Liabilities
0.18
+10.37%
0.16
+20.59%
0.14
-94.38%
2.42
Non Current Deferred Taxes Liabilities
0.18
+10.37%
0.16
+20.59%
0.14
0.00
Other Non Current Liabilities
0.42
-48.96%
0.82
-99.17%
99.01
+39663.86%
0.25
Stockholders Equity
303.10
-19.91%
378.43
+44.81%
261.33
-39.35%
430.91
Common Stock Equity
303.10
-19.91%
378.43
+44.81%
261.33
-39.35%
430.91
Capital Stock
0.05
-1.96%
0.05
+4.08%
0.05
-5.77%
0.05
Common Stock
0.05
-1.96%
0.05
+4.08%
0.05
-5.77%
0.05
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
50.92
-7.04%
54.77
+6.34%
51.50
-3.79%
53.53
Ordinary Shares Number
50.92
-7.04%
54.77
+6.34%
51.50
-3.79%
53.53
Additional Paid In Capital
1,043.92
+3.03%
1,013.19
+7.05%
946.51
+5.31%
898.81
Retained Earnings
-735.36
-17.42%
-626.24
+7.67%
-678.27
-47.31%
-460.44
Gains Losses Not Affecting Retained Earnings
-5.51
+35.64%
-8.57
-23.06%
-6.96
+7.20%
-7.50
Other Equity Adjustments
-5.51
+35.64%
-8.57
-23.06%
-6.96
+7.20%
-7.50
Total Equity Gross Minority Interest
303.10
-19.91%
378.43
+44.81%
261.33
-39.35%
430.91
Total Capitalization
303.10
-19.91%
378.43
+44.81%
261.33
-39.35%
430.91
Working Capital
167.28
-36.26%
262.46
+11.38%
235.64
-24.44%
311.87
Invested Capital
303.10
-19.91%
378.43
+44.81%
261.33
-39.35%
430.91
Total Debt
26.19
-7.66%
28.37
-17.11%
34.22
-12.25%
39.00
Capital Lease Obligations
26.19
-7.66%
28.37
-17.11%
34.22
-12.25%
39.00
Net Tangible Assets
230.81
-23.04%
299.91
+71.09%
175.29
-49.97%
350.34
Tangible Book Value
230.81
-23.04%
299.91
+71.09%
175.29
-49.97%
350.34
Current Provisions
3.50
—
—
—
Derivative Product Liabilities
—
—
0.00
-100.00%
0.03
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
42.03
+10.47%
38.05
+306.92%
-18.39
+27.14%
-25.24
Cash Flow From Continuing Operating Activities
42.03
+10.47%
38.05
+306.92%
-18.39
+27.14%
-25.24
Net Income From Continuing Operations
-21.35
-140.64%
52.55
+127.62%
-190.28
-148.37%
-76.61
Depreciation Amortization Depletion
20.42
+3.34%
19.76
-0.34%
19.82
+23.85%
16.01
Depreciation
20.42
+3.34%
19.76
-0.34%
19.82
+23.85%
16.01
Depreciation And Amortization
20.42
+3.34%
19.76
-0.34%
19.82
+23.85%
16.01
Other Non Cash Items
0.70
-24.49%
0.93
+63.91%
0.57
-21.87%
0.73
Stock Based Compensation
34.86
-47.50%
66.41
+35.29%
49.09
+5.44%
46.55
Asset Impairment Charge
2.26
0.00
-100.00%
1.00
+19.05%
0.84
Deferred Tax
0.02
+109.09%
-0.19
-133.04%
0.57
—
Deferred Income Tax
0.02
+109.09%
-0.19
-133.04%
0.57
—
Operating Gains Losses
0.05
-47.25%
0.09
+136.40%
-0.25
-133.64%
-0.11
Gain Loss On Investment Securities
—
—
-0.29
-174.77%
-0.11
Unrealized Gain Loss On Investment Securities
—
0.00
0.00
-100.00%
1.18
Change In Working Capital
3.81
+103.73%
-102.12
-196.31%
106.03
+845.79%
-14.22
Change In Receivables
22.52
+263.90%
-13.74
-185.80%
16.02
+340.48%
-6.66
Changes In Account Receivables
22.52
+263.90%
-13.74
-185.80%
16.02
+340.48%
-6.66
Change In Inventory
-4.96
-387.13%
-1.02
-1985.19%
0.05
+101.89%
-2.86
Change In Prepaid Assets
-4.41
-828.22%
0.61
-65.70%
1.77
+268.45%
-1.05
Change In Payables And Accrued Expense
-3.35
+95.93%
-82.10
-187.71%
93.61
+425400.00%
0.02
Change In Accrued Expense
-4.15
+94.61%
-76.99
-184.88%
90.71
+4269.27%
2.08
Change In Payable
0.81
+115.81%
-5.11
-275.96%
2.90
+241.38%
-2.05
Change In Account Payable
0.81
+115.81%
-5.11
-275.96%
2.90
+241.38%
-2.05
Change In Other Working Capital
—
-0.19
-133.04%
0.57
+363.26%
-0.21
Change In Other Current Liabilities
-6.00
-2.29%
-5.86
-8.21%
-5.42
-56.77%
-3.46
Investing Cash Flow
2.16
+546.79%
-0.48
-101.19%
40.45
+117.70%
-228.50
Cash Flow From Continuing Investing Activities
2.16
+546.79%
-0.48
-101.19%
40.45
+117.70%
-228.50
Capital Expenditure
-6.59
-1.60%
-6.48
+29.83%
-9.24
+62.03%
-24.33
Capital Expenditure Reported
-5.91
+8.81%
-6.48
+22.29%
-8.34
+60.70%
-21.23
Net Investment Purchase And Sale
8.75
+45.74%
6.00
-89.35%
56.37
+127.69%
-203.56
Purchase Of Investment
-145.93
+9.32%
-160.92
+20.39%
-202.13
+35.86%
-315.14
Sale Of Investment
154.67
-7.34%
166.92
-35.43%
258.50
+131.66%
111.59
Net Business Purchase And Sale
0.00
0.00
+100.00%
-6.68
-995.41%
-0.61
Purchase Of Business
0.00
0.00
+100.00%
-6.68
-995.41%
-0.61
Net Intangibles Purchase And Sale
-0.68
0.00
+100.00%
-0.90
+71.10%
-3.10
Purchase Of Intangibles
-0.68
0.00
+100.00%
-0.90
+71.10%
-3.10
Financing Cash Flow
-93.39
-1565.97%
-5.61
+81.06%
-29.61
-552.83%
-4.54
Cash Flow From Continuing Financing Activities
-93.39
-1565.97%
-5.61
+81.06%
-29.61
-552.83%
-4.54
Net Issuance Payments Of Debt
—
—
0.00
0.00
Repayment Of Debt
—
—
0.00
0.00
Long Term Debt Payments
—
—
0.00
0.00
Net Long Term Debt Issuance
—
—
0.00
0.00
Net Common Stock Issuance
-87.77
-16713.79%
-0.52
+98.10%
-27.54
-4189.88%
-0.64
Common Stock Payments
-87.77
-16713.79%
-0.52
+98.10%
-27.54
-4189.88%
-0.64
Repurchase Of Capital Stock
-87.77
-16713.79%
-0.52
+98.10%
-27.54
-4189.88%
-0.64
Proceeds From Stock Option Exercised
8.00
-22.63%
10.33
+538.23%
1.62
-65.29%
4.67
Net Other Financing Charges
-13.62
+11.65%
-15.42
-318.49%
-3.68
+56.95%
-8.56
Changes In Cash
-49.20
-253.96%
31.96
+523.41%
-7.55
+97.08%
-258.28
Effect Of Exchange Rate Changes
-0.09
-116.92%
0.53
+575.00%
-0.11
-586.96%
0.02
Beginning Cash Position
115.27
+39.25%
82.78
-8.47%
90.44
-74.06%
348.70
End Cash Position
65.98
-42.76%
115.27
+39.25%
82.78
-8.47%
90.44
Free Cash Flow
35.44
+12.29%
31.56
+214.25%
-27.63
+44.27%
-49.57
Interest Paid Supplemental Data
—
0.00
0.00
-100.00%
0.01
Income Tax Paid Supplemental Data
0.28
-10.41%
0.32
-57.05%
0.74
+88.27%
0.39
Amortization Of Securities
1.27
+104.99%
0.62
+112.60%
-4.93
-1363.33%
0.39
Common Stock Issuance
—
—
0.00
0.00
Issuance Of Capital Stock
—
—
0.00
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category